BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

VERX upcoming catalysts

Vertex Pharmaceuticals Incorporated: 2 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (1 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 5 readout(s) and 3 FDA event(s). Subscribe to VERX (.ics).

Drugs: Suzetrigine

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
No upcoming PDUFA date or AdCom found.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2027-01-25 est.P3Vertex Pharmaceuticals Incorporated VERXNCT06696443 Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)Diabetic Peripheral Neuropathic Painactive not recruiting455
2027-02-02 est.P1/P2Vertex Pharmaceuticals Incorporated VERXNCT06185764 A Phase 1/2 Study of VX-670 in Adult Participants With Myotonic Dystrophy 1 (DM1)Myotonic Dystrophy Type 1 (DM1)active not recruiting47

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-03-27FDA approvalapprovedVERTEX PHARMS INC VERXTRIKAFTAApproved 2026-03-27: TRIKAFTA (COPACKAGED) (NDA212273 SUPPL14)
2026-03-27FDA approvalapprovedVERTEX PHARMS INC VERXALYFTREKApproved 2026-03-27: ALYFTREK (NDA218730 SUPPL1)
2026-03-27FDA approvalapprovedVERTEX PHARMS INC VERXTRIKAFTAApproved 2026-03-27: TRIKAFTA (COPACKAGED) (NDA217660 SUPPL8)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
2026-10-30 est.P3Vertex Pharmaceuticals Incorporated VERXNCT05444257 A Study Evaluating the Long-term Safety and Efficacy of VX-121 Combination TherapyCystic Fibrosisactive not recruiting822
2026-09-17 est.P3Vertex Pharmaceuticals Incorporated VERXNCT06832410 An Efficacy, Safety, and Tolerability Study of VX-880 in Participants With Type 1 Diabetes With a Kidney TransplantType 1 Diabetes; Kidney Transplantrecruiting10
2026-07-20P2Vertex Pharmaceuticals Incorporated VERXNCT06794996 Inaxaplin in Participants With Proteinuric APOL1 Mediated Kidney Disease With or Without ComorbiditiesProteinuric Kidney Diseasecompleted42
2026-04-21P1/P2Vertex Pharmaceuticals Incorporated VERXNCT05668741 A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)Cystic Fibrosiscompleted26
2026-01-29P3Vertex Pharmaceuticals Incorporated VERXNCT05153317 Evaluation of Long-term Safety and Efficacy of ELX/TEZ/IVA in Cystic Fibrosis (CF) Participants 2 Years and OlderCystic Fibrosiscompleted71

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.